Press coverage about Biomerica (NASDAQ:BMRA) has trended positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biomerica earned a news sentiment score of 0.29 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.4796074624669 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Biomerica (BMRA) remained flat at $$3.40 during mid-day trading on Tuesday. The stock had a trading volume of 2,800 shares, compared to its average volume of 15,355. Biomerica has a 52-week low of $1.91 and a 52-week high of $3.85.
Biomerica (NASDAQ:BMRA) last released its earnings results on Monday, October 16th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $1.52 million. Biomerica had a negative net margin of 14.33% and a negative return on equity of 18.93%.
Separately, ValuEngine cut shares of Biomerica from a “hold” rating to a “sell” rating in a report on Friday, August 11th.
TRADEMARK VIOLATION WARNING: “Positive Media Coverage Somewhat Unlikely to Impact Biomerica (BMRA) Share Price” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thestockobserver.com/2017/11/14/positive-media-coverage-somewhat-unlikely-to-impact-biomerica-bmra-share-price.html.
Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).
Receive News & Ratings for Biomerica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.